Drug Approval | April 04, 2025
Gland Pharma receives approval for Acetaminophen Injection
The company expects to launch this product through its marketing partner in the near future
The company expects to launch this product through its marketing partner in the near future
The IND application supports the next phase of development of SBO-154
The inspection has concluded with four observations
Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
Abbott's investigational Coronary Intravascular Lithotripsy (IVL) System offers a new potential treatment by using sound pressure waves to treat arterial calcium blockages
Alembic Pharmaceuticals successfully completes USFDA inspection for API-III facility
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Apitoria Pharma’s API manufacturing facility classified as VAI by USFDA
Apalutamide is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive prostate cancer
Subscribe To Our Newsletter & Stay Updated
